PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. Issue 12 (December 2020) - Tew, William P.
Abstract : (Abstracted from J Clin Oncol 2020;38:3468–3493) Despite advances in diagnosis and therapy, an individual with ovaries carries an approximate 1 in 108 lifetime chance to die due to ovarian cancer (OC). Primary therapy typically involves surgical cytoreduction and a combination regimen of platinum and a taxane.